The Oncofetal Paradigm Revisited: MSF and HA as Contextual Drivers of Cancer Progression

Hyaluronan in Cancer Biology

Volumn , Issue , 2009, Pages 285-306

  Schor, Seth L ^a   Schor, Ana M ^a   Ellis, Ian R ^a   Jones, Sarah J ^a   Florence, Margaret ^a   Cox, Jacqueline ^a   Woolston, Anne Marie ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857507940     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012374178-3.10015-8     Document Type: Chapter

References (51)

1. Amanuma K., Mitsui Y. HA synthesis is absent in normal human endothelial cells irrespective of HA synthase inhibitor activity but is significantly high in transformed cells. Biochem Biophys Acta 1991, 1093:336-340.
2. Azzarone B., Mareel M., Billard C., et al. Abnormal properties of skin fibroblasts from patients with breast cancer. Int J Cancer 1984, 33:759-764.
3. Bakheet T., Frevel M., Williams B.R.G., Greer W., Khabar K.S.A. ARED: human AU-rich element-containing mRNA database reveals an unexpectedly diverse functional repertoire of encoded proteins. Nucleic Acid Res 2001, 29:246-254.
4. Chen C.-Y.A., Chen T.-M., Shyu A.-B. Interplay of two functionally and structurally distinct domains of the c-fos AU-rich element specifies its mRNA-destabilizing function. Mol Cell Biol 1994, 14:416-426.
5. Chen W.Y.J., Grant M.E., Schor A.M., Schor S.L. Differences between adult and fetal fibroblasts in the regulation of hyaluronate synthesis: correlation with migratory activity. J Cell Sci 1989, 94:577-584.
6. Clark R.A.F., Wikner N.E., Doherty D.E., Norris D.A. Cryptic chemotactic activity of fibronectin for human monocytes resides in the 120-kDa fibroblastic cell-binding fragment. J Biol Chem 1998, 263:12115-12123.
7. Durning P., Schor S.L., Sellwood R.A. Fibroblasts from patients with breast cancer show abnormal migratory behaviour in vitro. Lancet 1984, 2:890-892.
8. Eads C.A., Lord R.V., Kurumboor S.K., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res 2000, 60:5021-5026.
9. Ellis I., Banyard J., Schor S.L. Differential response of fetal and adult fibroblasts to cytokines, cell migration and hyaluronan synthesis. Development 1997, 124:1593-1600.
10. Ellis I., Grey A.M., Schor A.M., Schor S.L. Antagonistic effects of TGFβ1 and MSF on fibroblast migration and hyaluronic acid synthesis - possible implications for dermal wound healing. J Cell Sci 1992, 102:447-456.
11. Ellis I.R., Schor A.M., Schor S.L. EGF and TGF-alpha motogenic activities are mediated by the EGF receptor via distinct matrix-dependent mechanisms. Exp Cell Res 2007, 313:732-741.
12. ffrench-Constant C., Van de Water L., Dvorak H.F., Hynes R.O. Reappearance of an embryonic pattern of fibronectin splicing during wound healing in the adult rat. J Cell Biol 1989, 109:903-914.
13. Fukai F., Suzuki H., Suzuki K., Tsugita A., Katayama T. Rat plasma fibronectin contains two distinct chemotactic domains for fibroblastic cells. J Biol Chem 1991, 246:8807-8813.
14. Fukai F., Iso T., Sekiguchi K., et al. An amino-terminal fibronectin fragment stimulates the differentiation of ST-13 preadipocytes. Biochemistry 1993, 32:5746-5751.
15. Fukai F., Ohtaki M., Fugii N., et al. Release of biological activities from quiescent fibronectin by a conformational change and limited proteolysis by matrix metalloproteinases. Biochemistry 1995, 34:11453-11459.
16. Haggie J.A., Sellwood R.A., Howell A., Birch J.M., Schor S.L. Fibroblasts from relatives of patients with hereditary breast cancer show fetal-like behaviour in vitro. Lancet 1987, 1:1455-1457.
17. Houard X., Germain S., Gervais M., et al. Migration-stimulating factor displays HEXXH-dependent catalytic activity important for promoting tumor cell migration. Int J Cancer 2005, 116:378-384.
18. Ilyas M., Straub J., Tomlinson I.P., Bodmer W.P. Genetic pathways in colorectal and other cancers. Eur J Cancer 1999, 35:1986-2002.
19. Hynes R. Fibronectins. 1990, Springer-Verlag, New York.
20. Jones S.J., Florence M.M., Ellis I.R., et al. Co-expression by keratinocytes of migration stimulating factor (MSF) and functional inhibitor of its bioactivity (MSFI). Exp Cell Res 2007, 313:4145-4157.
21. Kay R.A., Ellis I.R., Jones S.J., et al. The expression of MSF, a potent oncofetal cytokine, is uniquely controlled by 3'-untranslated region dependent nuclear sequestration of its precursor messenger RNA. Cancer Res 2005, 65:10742-10749.
22. Kopelovich L. The transformed (initiated) human cell phenotype: studies on cultured skin fibroblasts from individuals predisposed to cancer. Mutat Res 1988, 199:369-385.
23. Liu X., Zhao Q., Collodi P. A truncated form of fibronectin is expressed in fish and mammals. Matrix Biol 2003, 22:393-396.
24. McNeal R. Anatomy of the prostate and morphogenesis of BPH. New Approaches to the Study of Benign Prostatic Hyperplasia. 1984, 27-53. A.R. Liss, New York. F.A. Kimbal, A.E. Buhl, D.B. Carter (Eds.).
25. Millard C.J., Ellis I.R., Pickford A.R., et al. The role of fibronectin IGD motif in stimulating fibroblast migration. J Biol Chem 2007, 282:35530-35535.
26. Muir D., Manthorpe M. Stromelysin generates a fibronectin fragment that inhibits Schwann cell proliferation. J Cell Biol 1992, 116:177-185.
27. Nees M., Hormann N., Discher H., et al. Expression of mutated p53 of tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. Cancer Res 1993, 53:4189-4196.
28. Nielsen M., Thomsen J.L., Primdahl S., Dyreborg U., Andersen J.A. Breast cancer and atypia among young and middle-aged women. Br J Cancer 1987, 56:814-819.
29. Picardo M., Schor S.L., Grey A.M., et al. Migration stimulating activity in serum of breast cancer patients. Lancet 1991, 337:130-133.
30. Picardo M., Grey A.M., McGurk M., Ellis I., Schor S.L. Detection of migration stimulating activity in wound fluid. Exp Mol Pathol 1992, 57:8-21.
31. Schor A.M., Rushton G., Ferguson J.E., et al. Phenotypic heterogeneity in breast fibroblasts - functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int J Cancer 1994, 59:25-32.
32. Schor A.M., Pendleton N., Pazouki S., et al. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem J 1998, 30:849-856.
33. Schor S.L. Cell proliferation and migration on collagen substrata in vitro. J Cell Sci 1980, 41:159-175.
34. Schor S.L. Cytokine control of cell motility: modulation and mediation by the extracellular matrix. Prog Growth Factor Res 1994, 5:223-248.
35. Schor S.L., Schor A.M. Stromal acceleration of tumour progression: role of fetal-like fibroblast subpopulations. Pathol Update 1997, 4:75-95.
36. Schor S.L., Schor A.M. Tumour-stroma interactions - phenotypic and genetic alterations in mammary stroma: implications for tumour progression. Breast Cancer Res 2001, 3:373-379.
37. Schor S.L., Schor A.M., Rushton G., Smith L. Adult, foetal and transformed fibroblasts display different migratory phenotypes on collagen gels - evidence for an isoformic transition during foetal development. J Cell Sci 1985, 73:221-234.
38. Schor S.L., Schor A.M., Durning P., Rushton G. Skin fibroblasts from cancer patients display foetal-like migratory behaviour on collagen gels. J Cell Sci 1985, 73:235-244.
39. Schor S.L., Schor A.M., Howell A., Crowther D. Hypothesis: persistent expression of fetal phenotypic characteristics by fibroblasts is associated with increased susceptibility to malignant disease. Eur Exp Cell Biol 1987, 55:11-17.
40. Schor S.L., Schor A.M., Grey A.M., Rushton G. Fetal and cancer patient fibroblasts produce an autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci 1988, 90:391-399.
41. Schor S.L., Schor A.M., Rushton G. Fibroblasts from cancer patients display a mixture of both fetal and adult-like phenotypic characteristics. J Cell Sci 1988, 90:401-407.
42. Schor S.L., Schor A.M., Grey A.M., et al. Mechanism of action of the migration stimulating factor produced by fetal and cancer-patient fibroblasts: effect on hyaluronic acid synthesis. In vitro Cell Dev Biol 1989, 25:737-746.
43. Schor S.L., Ellis I., Dolman C., et al. Substratum-dependent stimulation of fibroblast migration by the gelatin-binding domain of fibronectin. J Cell Sci 1996, 109:2581-2590.
44. Schor S.L., Ellis I., Banyard J., Schor A.M. Motogenic activity of the IGD amino acid motif. J Cell Sci 1999, 112:3879-3888.
45. Schor S.L., Ellis I.R., Jones S.J., et al. Migration-stimulating factor: a genetically truncated onco-fetal fibronectin isoform expressed by carcinoma and tumor-associated stromal cells. Cancer Res 2003, 63:8827-8836.
46. Schor S.L., Schor A.M., Keatch R.P., Belch J.F.F. Role of matrix macromolecules in the aetiology and treatment of chronic ulcers. The Wound Management Manual. 2005, 109-121. McGraw Hill, New York, Chapter 10. B.Y. Lee (Ed.).
47. Shen L., Kondo Y., Rosner G.L., et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005, 97:1330-1338.
48. Werb Z., Tremble P.M., Behrendsten O., Cowley E., Damsky C.H. Signal transduction through fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989, 109:877-889.
49. Winterbourne D., Schor A.M., Gallagher J.T. Synthesis of GAGs by cloned bovine endothelial cells cultured on collagen gels. Eur J Biochem 1983, 135:271-277.
50. Zhao Q., Liu X., Collodi P. Identification and characterization of a novel fibronectin in Zebrafish. Exp Cell Res 2001, 268:211-219.
51. Zigmond S.H., Hirsch J.G. Leukocyte locomotion and chemotaxis. New methods for evaluation and demonstration of a cell derived chemotactic factor. J Exp Med 1973, 137:387-410.